Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Jakobovits Aya	2. Issuer Name and Ticker or Trading Symbol Adicet Bio, Inc. [ ACET ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6	3. Date of Earliest Transaction (MM/DD/YYYY) 1/3/2022
(Street) BOSTON, MA 02116 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	1/3/2022		S⁽¹⁾		6000	D	$18.0208 ⁽²⁾	366343	I	See Footnote ⁽³⁾
Common Stock	1/3/2022		S⁽¹⁾		6000	D	$18.0218 ⁽⁴⁾	366345	I	See Footnote ⁽⁵⁾
Common Stock	1/5/2022		S⁽¹⁾		2000	D	$16.932 ⁽⁶⁾	364343	I	See Footnote ⁽³⁾
Common Stock	1/5/2022		S⁽¹⁾		2000	D	$16.8995 ⁽⁷⁾	364345	I	See Footnote ⁽⁵⁾
Common Stock	2/9/2022		S⁽¹⁾		4000	D	$14.0294 ⁽⁸⁾	360343	I	See Footnote ⁽³⁾
Common Stock	2/9/2022		S⁽¹⁾		4000	D	$14.0303 ⁽⁹⁾	360345	I	See Footnote ⁽⁵⁾
Common Stock								138076	I	See Footnote ⁽¹⁰⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.
(2)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(3)	Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.
(4)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(5)	Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.
(6)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(7)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(8)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(9)	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
(10)	Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Jakobovits Aya C/O ADICET BIO, INC. 200 CLARENDON STREET, FLOOR 6 BOSTON, MA 02116	X